Moksonydyn | Physiotens tablets are covered. 0.2 mg 28 pcs.

Pharmacological action

Moxonidine is a hypotensive drug with a central mechanism of action. In the stem structures of the brain (the rostral layer of the lateral ventricles), moxonidine selectively stimulates imidazoline-sensitive receptors, taking part in the tonic and reflex regulation of the sympathetic nervous system. Stimulation of imidazoline receptors reduces peripheral sympathetic activity and blood pressure (BP).

Moxonidine differs from other sympatholytic antihypertensive agents in lower affinity for a2-adrenergic receptors, which explains the lesser likelihood of developing a sedative effect and dry mouth.

Taking moxonidine leads to a decrease in systemic vascular resistance and blood pressure. The hypotensive effect of moxonidine is confirmed in double-blind, placebo-controlled, randomized trials.

Moxonidine improves the insulin sensitivity index (compared to placebo) by 21% in patients with obesity, insulin resistance, and moderate arterial hypertension.

Pharmacokinetics

Absorption:

After oral administration, moxonidine is rapidly and almost completely absorbed in the upper gastrointestinal tract. Absolute bioavailability is approximately 88%. The time to reach maximum concentration is about 1 hour. Eating does not affect the pharmacokinetics of the drug.

Distribution of

Communication with plasma proteins is 7.2%.

Metabolism

The main metabolite is dehydrogenated moxonidine. The pharmacodynamic activity of dehydrogenated moxonidine is about 10% compared with moxonidine.

Excretion

The elimination half-life (T1 / 2) of moxonidine and the metabolite is 2.5 and 5 hours, respectively. Within 24 hours, over 90% of moxonidine is excreted by the kidneys (about 78% unchanged and 13% in the form of dehydrromoxonidine, other metabolites in the urine do not exceed 8% of the dose). Less than 1% of the dose is excreted through the intestines.

Pharmacokinetics in patients with arterial hypertension:

Compared to healthy volunteers, patients with arterial hypertension did not show changes in the pharmacokinetics of moxonidine.

Pharmacokinetics in the elderly

Clinically insignificant changes in the pharmacokinetic parameters of moxonidine in elderly patients have been noted, probably due to a decrease in its metabolic rate and / or slightly higher bioavailability.

Pharmacokinetics in children

Moxonidine is not recommended for use in persons under 18 years of age, and therefore pharmacokinetic studies have not been conducted in this group.

Pharmacokinetics for renal failure

Excretion of moxonidine is significantly correlated with creatinine clearance (CC). In patients with moderate renal failure (CC in the range of 30-60 ml / min), equilibrium plasma concentrations and final T1 / 2 are approximately 2 and 1.5 times higher than in individuals with normal renal function (CC more than 90 ml / min.). In patients with severe renal failure (CC less than 30 ml / min.), Equilibrium plasma concentrations and final T1 / 2 are 3 times higher than in patients with normal renal function. The administration of multiple doses of moxonidine leads to predictable cumulation in the body of patients with moderate and severe renal failure. In patients with terminal renal failure (CC less than 10 ml / min) on hemodialysis, the equilibrium plasma concentrations and final T1 / 2 are 6 and 4 times higher, respectively, than in patients with normal renal function. In all groups, the maximum concentration of moxonidine in blood plasma is 1.5 to 2 times higher. In patients with impaired renal function, the dosage should be selected individually. Moxonidine is slightly excreted during hemodialysis.

Indications

Arterial hypertension.

Contraindications

Hypersensitivity to the active substance and other components of the drug, sinus node weakness syndrome, severe bradycardia (resting heart rate (HR) less than 50 beats. / min).

Hereditary galactose intolerance, lactase deficiency or malabsorption of glucose-galactose.

Due to the lack of safety and efficacy data, the administration of moxonidine to persons under 18 years of age is not recommended.

Caution: severe and terminal renal failure in patients undergoing hemodialysis due to a lack of experience in use - severe hepatic insufficiency (more than 9 points according to the Child-Pyug classification).

compав

Active ingredient: moxonidine 0.2 mg.

Excipients: lactose monohydrate - 95.80 mg, povidone - 0.70 mg, crospovidone - 3.00 mg, magnesium stearate - 0.30 mg.

Shell: hypromellose - 1.30 mg, ethyl cellulose - 1.20 mg, macrogol - 0.25 mg, talc - 0.9975 mg, dye iron oxide red (E 172) - 0.0025 mg, titanium dioxide (E 171 ) - 1.25 mg.

Dosage and administration

Inside, regardless of food intake.

In most cases, the initial dose of Physiotens® is 0.2 mg per day. The maximum single dose is 0.4 mg. The maximum daily dose, which should be divided into 2 doses, is 0.6 mg.

Daily dose for patients with moderate or severe renal failure, as well as those on hemodialysis - 0.2 mg. If necessary and with good tolerance, the daily dose can be increased to 0.4 mg.

Side effects of

From the central nervous system:

Often (1-10%): headache, dizziness, drowsiness.

Infrequently (<1%): insomnia.

From the cardiovascular system:

Rarely (<0.1%): excessive decrease in blood pressure, orthostatic hypotension.

From the gastrointestinal tract:

Often (1-10%): dry mouth.

Infrequently (<1%): nausea.

From the skin and subcutaneous fat

Uncommon (<1%): skin rash, itching.

Very rare (<0.01%): angioedema.

General:

Often (1-10%): asthenia.

The most common side effects in patients taking moxonidine are dry mouth, headache, dizziness, asthenia, and drowsiness. These symptoms often diminish after the first weeks of therapy.

Overdose

There have been reports of several cases of overdose without fatal outcome, when doses up to 19.6 mg were used simultaneously.

Symptoms: headache, sedation, drowsiness, marked decrease in blood pressure, dizziness, fatigue, asthenia, bradycardia, dry mouth, vomiting, and pain in the epigastric region. A short-term increase in blood pressure, tachycardia, hyperglycemia are also potentially possible.

Treatment for

There is no specific antidote. In the case of lowering blood pressure, it is recommended to restore the volume of circulating blood due to the introduction of fluid and the introduction of dopamine.

Bradycardia can be stopped with atropine.

Alpha-adrenergic antagonists can reduce or eliminate the paradoxical hypertensive effects of an overdose of moxonidine.

Active ingredient

moxonidine



pharmacy terms for prescription

The dosage form of

tablet